Are Hester Biosciences Ltd latest results good or bad?

Hester Biosciences Ltd's latest financial results for Q4 FY26 indicate a notable operational turnaround compared to the previous year. The company reported a consolidated net profit of ₹15.98 crores, reflecting a significant year-on-year growth of 1,138.76%, a stark contrast to the near-zero profitability recorded in the same quarter last year. Additionally, revenue reached ₹100.11 crores, marking a year-on-year increase of 22.19% and surpassing previous quarterly records. The operating margin for this quarter stood at 34.29%, which is the highest in the company's history, showcasing substantial margin expansion driven by improved operational efficiencies and cost management. This margin represents a significant improvement from the prior year's figures, indicating a strong recovery in profitability. Sequentially, the results also demonstrate positive momentum, with net profit increasing by 82.21% from ₹8.77 crores in Q3 FY26 and revenue growing by 29.31% from ₹77.42 crores in the previous quarter. This growth suggests a robust demand environment, particularly in the animal healthcare segment, which typically experiences seasonal strength in the March quarter. Despite these positive developments, the company faces challenges, particularly with rising interest expenses, which surged by 180.22% quarter-on-quarter. This increase in interest costs could impact future profitability if not managed effectively. In terms of balance sheet health, Hester Biosciences has made progress in deleveraging, with long-term debt decreasing from ₹182.09 crores in FY24 to ₹133.37 crores in FY25. However, the debt-to-EBITDA ratio remains elevated, indicating ongoing leverage concerns relative to earnings capacity. Overall, Hester Biosciences Ltd's recent results reflect a significant operational recovery and margin expansion, although the company is navigating challenges related to interest costs and long-term financial metrics. The company saw an adjustment in its evaluation, reflecting the mixed signals across various financial parameters.